Lung cancer is the second most common cancer and accounts for 14% of new cancers (1). It is the leading cause of cancer deaths in the United Kingdom, the most frequent cause of major cancer incidence and mortality in men, and the second most common cause of cancer mortality in women (2,3). In 2010, over 42,000 people were diagnosed with lung cancer and there were nearly 35,000 deaths (4). Non-small cell lung cancers account for around 85% of cases (1) and of these adenocarcinomas are most common (5,6). The prevalence of adenocarcinoma is increasing (7) and it presents frequently in asymptomatic females, especially those from East Asia, and often in non-smokers.

The radiological appearance of peripheral lung adenocarcinomas encompasses a spectrum from ground glass nodules (GGNs) to solid mass lesions on computed tomography (CT), reflecting their heterogeneous histological subtypes. This spectrum was previously referred to using the single term bronchoalveolar cell carcinoma (BAC) which frequently caused confusion (8). It became clear that a more robust classification was required and with advances in understanding of the oncology, molecular biology, pathology, radiology and surgery of lung adenocarcinoma this became possible.

The International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) classification introduced new terminology to better reflect this heterogeneous group of adenocarcinomas formerly known as bronchoalveolar cell carcinoma (BAC). There is now a clear distinction between pre-invasive, minimally invasive and frankly invasive lesions. The radiographic appearance of these ranges from pure ground glass nodules to solid mass lesions. Radiologists must be aware of the new classification in order to work alongside multidisciplinary colleagues to allow accurate staging and treatment. This article reviews the new classification of lung adenocarcinomas. Management options of these lesions with particular focus on radiological implications of the new classification will be reviewed.

**Keywords:** Adenocarcinoma; bronchiolo-alveolar; non-small cell lung cancer; computed tomography (CT); multiple pulmonary nodules; solitary pulmonary nodules
pre-invasive lesions. These lesions are likely to be picked up with increasing frequency in lung cancer screening studies. This article describes the terminology used in the new classification and discusses associated prognostic implications. Radiographic appearances of the lung adenocarcinoma spectrum will be reviewed with pathologic correlation, and management options discussed.

**The revised lung adenocarcinoma (IASLC/ATS/ERS) classification**

One of the strongest recommendations of the new classification is to discontinue use of the term BAC. Previously this term was applied to tumours with a pure bronchioloalveolar growth pattern characterised by lepidic growth—growth of neoplastic cells along pre-existing structures and alveolar septa without invasion of the stoma, pleura or vessels (11). Lepidic growth manifests radiologically as ground glass opacification (6) hence the importance of the GGN.

Work by Noguchi et al. in the 1990s demonstrated that patients with GGNs had a better prognosis than those with solid nodules (12). This was reflected in the 1999 (13) and 2004 (14) WHO classifications of lung cancer. The evolution of GGNs (typically lepidic growth) to more solid (and so more likely invasive) nodules was well documented prior to the revised classification (15). Data from lung cancer screening literature shows a higher rate of malignancy in incidental part-solid nodules compared to incidental solid nodules (16) and the majority of persistent GGNs represent adenocarcinoma spectrum lesions (17,18).

The previous classification of BAC included a heterogenous spectrum of subtypes including mucinous, non-mucinous and mixed. This frequently caused confusion due to their varied radiological appearance (19). The term was applied to invasive and non-invasive adenocarcinomas with varying prognoses ranging from 100% 5 years survival following resection of non-invasive lesions (20) to less than 10% 3 years survival for some invasive adenocarcinomas (21).

The revised classification better reflects the pathologic, radiologic and clinical correlation of lung adenocarcinoma. What was previously classified as BAC is now categorized into the following terms—adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), lepidic predominant adenocarcinoma (LPA), predominantly invasive adenocarcinoma with some nonmucinous lepidic component and invasive mucinous adenocarcinoma. Table 1 demonstrates the revised classification, which more clearly follows the multistep progression that many lung adenocarcinoma spectrum lesions are thought to take (22). This allows better differentiation between pre-invasive, minimally invasive and frankly invasive lesions. Figure 1 demonstrates the definitions of nodules as used in the new classification.

There is good inter-observer agreement between pathologists using the new classification (23) though few studies have investigated agreement between radiologists. The new classification better reflects the varying prognoses associated with these lesions. Radiologists must be able to distinguish invasive mucinous adenocarcinoma from non-mucinous predominant pre-invasive adenocarcinoma spectrum lesions as this impacts on treatment algorithms including surgical intervention, follow up planning and prognosis prediction (24).

**Radiographic appearances of the new classification**

**Pre-invasive lesions**

**Atypical adenomatous hyperplasia (AAH)**

AAH is the earliest detectable pre-invasive lesion and is equivalent to the term squamous dysplasia. Its histologic and radiologic features predate the new classification and

<table>
<thead>
<tr>
<th>Table 1 The revised classification of lung adenocarcinoma (6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preinvasive lesions</td>
</tr>
<tr>
<td>i. Adenocarcinoma in situ (AIS) —mucinous, nonmucinous, or mixed</td>
</tr>
<tr>
<td>ii. Atypical adenomatous hyperplasia (AAH)</td>
</tr>
<tr>
<td>Minimally invasive lesions</td>
</tr>
<tr>
<td>i. Minimally invasive adenocarcinomas (MIA) —mucinous, nonmucinous, or mixed</td>
</tr>
<tr>
<td>Invasive adenocarcinoma</td>
</tr>
<tr>
<td>i. Acinar predominant</td>
</tr>
<tr>
<td>ii. Papillary predominant</td>
</tr>
<tr>
<td>iii. Micropapillary predominant</td>
</tr>
<tr>
<td>iv. Solid predominant with mucin production</td>
</tr>
<tr>
<td>v. Lepidic predominant adenocarcinoma (LPA)</td>
</tr>
<tr>
<td>Variants of invasive adenocarcinoma</td>
</tr>
<tr>
<td>i. Invasive mucinous adenocarcinoma</td>
</tr>
<tr>
<td>ii. Colloid, fetal, and enteric</td>
</tr>
</tbody>
</table>

IASLC/ATS/ERS classification of lung adenocarcinoma in resection specimens; IASLC/ATS/ERS, the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society.
so are well validated. AAH manifests as a small GGN typically less than 5 mm in size with no solid or part-solid component (19). Bronchial and vascular margins are preserved and AAH is less opaque than AIS. Histologically there is proliferation of mild to moderately atypical cuboidal to columnar epithelial cells along alveoli and respiratory bronchioles, with no invasion. Adenocarcinoma spectrum lesions are often multifocal and AAH is often found adjacent to resected invasive adenocarcinomas. Figure 2 demonstrates one such case of pure ground glass nodules typical of AAH. There is a continuum of morphologic changes between AAH and AIS and histopathologists are adjusting to the new classification and its application (23,25).

Adenocarcinoma in situ (AIS)
AIS refers to purely lepidic growth without stromal, vascular or pleural invasion. It is equivalent to carcinoma in situ. Like AAH it is a pre-invasive tumour but is typically larger. Most measure between 5 and 20 mm but AIS can be as large as 3 cm. Although still a GGN, AIS is typically of greater attenuation than AAH. Figure 3 demonstrates a GGN of higher attenuation than that characteristic of AAH and its pathologic correlate.

Invasive lesions
Minimally invasive adenocarcinoma (MIA)
MIA describes a solitary adenocarcinoma 3 cm or less in size. Again this is a LPA but unlike the pre-invasive

Figure 1 Definition of nodules used in the classification of lung adenocarcinoma—based on the Fleishner Society glossary of terms (10).

Figure 2 (A) A persistent pure ground glass nodule (GGN) characteristic of atypical adenomatous hyperplasia (AAH); (B) a GGN which was superior to an invasive adenocarcinoma; (C) histologic specimen, hematoxylin and eosin (H and E) stain of the GGN demonstrating a 0.6 mm focus of atypical cuboidal to columnar epithelial cells along alveolar spaces.
lesions is characterized by a small invasive component of tumour cells infiltrating myofibroblastic stroma. Most MIA are non-mucinous. The actual size of the invasive component at histology is likely to measure no greater than 5 mm (26). This requires validation on CT as a variety of other associated components of small adenocarcinomas including collapse, fibrosis and mucous can also cause a solid appearance. Thus on CT the solid component may be larger (27). MIA is excluded if there is any invasion to lymphatics, pleura, blood vessels or tumour necrosis. Radiologically MIA manifests as a part-solid nodule in contrast to the GGNs of pre-invasive adenocarcinomas, the solid component representing the focus of invasion. Figure 4 demonstrates a part-solid nodule which proved to be MIA. Mucinous and non-mucinous MIA can present and solid and part-solid nodules.

Importantly MIA, as well as AIS, can be considered for sublobar resection (28). Differences between MIA and mucinous AIS are a greater size, an extent of invasion greater than 5 mm, multiple nodules, and the spread of the nodule into adjacent lung parenchyma with an indistinct border (29).

**Invasive adenocarcinoma**

Invasive adenocarcinoma is present when there is at least one invasive tumour focus measuring more than 5 mm in its greatest dimension (6). They represent over 70% of resected adenocarcinomas and consist of a heterogenous and complex mixture of histologic subtypes. Although previously referred to as adenocarcinoma of mixed subtype they are now classified according to their predominant histologic component principally acinar, papillary, micropapillary, solid and lepidic. Invasive adenocarcinomas are predominantly mucinous compared to the predominant non-mucinous...
pre-invasive lesions. Mucinous BAC has been reclassified as an invasive mucinous adenocarcinoma an example of which is shown in Figure 5. These are differentiated from non-mucinous tumours by the mucinous cells, which consist of columnar cells, abundant apical mucin and small basally orientated nuclei.

Invasive adenocarcinomas are typically solid or mostly solid on CT, frequently display air bronchograms, have a lobar or multilobar distribution and most often consist of nodular or consolidative opacities (30,31). When multifocal these were previously called multicentric BAC, a term now discontinued.

Lepidic predominant adenocarcinoma (LPA) describes an invasive adenocarcinoma with predominant lepidic growth pattern. Unlike MIA it consists of at least one focus of invasion into vessels, pleura or lymphatics, or is necrotic. LPA is applied to purely non-mucinous adenocarcinomas; any mucinous component would make it an invasive adenocarcinoma.

CT evaluation and measurement of part-solid nodules

Accurate assessment of part-solid nodules requires thin slice CT using slice thickness of less than 3 mm and ideally 1-1.5 mm (32,33). This allows accurate detection of subtle changes in ground glass attenuation and differentiation between ground glass and solid components as well as subtle changes in the size and solid component of the nodule (34).

The size of the invasive component, corresponding to the solid component of a nodule versus the ground glass lepidic component, correlates with prognosis. The radiologist should document the total size of any subsolid nodule as well as the size of any solid component due to the implications upon prognosis and treatment options of the solid component. The solid component should be measured on mediastinal windows to aid consistency (35) as demonstrated in Figure 6. With further validation studies it is likely that the T staging in future TNM classifications will relate not to the total size of a subsolid nodule but to the size of the solid component due to prognostic implications of an invasive component.

The margin of GGNs is less distinct than that of solid lesions, which can impede accurate and consistent measurement. Using commercial software can reduce variations in the volume and attenuation measurements (36) but currently there is no consensus on the optimum evaluation of subsolid nodules. Techniques such as histogram evaluation of attenuation (37) require validation. Current best practice is to use thin-slice CT, measure the solid component on mediastinal windows and also give the total size of the nodule including the ground glass component.

Radiological management of adenocarcinoma spectrum lesions

The differential diagnosis of subsolid nodules ranges from infection and focal interstitial fibrosis to malignant lung adenocarcinoma (38). Because the majority of GGNs will resolve the initial management of any GGN or subsolid nodule is a repeat scan. A persistent GGN is of greater malignant potential than an equivalent persistent
solid nodule \((17,18)\) and the differential diagnosis of a persistent GGN includes AAH, adenocarcinoma spectrum, lymphoproliferative disorder and also organizing pneumonia/fibrosis \((36)\).

Certain characteristics of a subsolid nodule can help determine the likelihood of invasion \((29)\) and the radiologist should be alert to the implications of these findings. The presence of air bronchograms, spiculate margins or pleural retraction suggest increased likelihood of invasion \((39)\) as does a concave notch in the solid component or lobular border \((40,41)\). In contrast, spherical pure GGNS are more likely to be preinvasive.

The size of a GGN correlates with invasive potential. A size of less than 10 mm is a highly specific discriminator of a preinvasive lesion over an invasive adenocarcinoma \((41)\). A separate study identified that a size of greater than 8 mm is an independent predictor of malignancy \((26)\). Any increase in the attenuation of a nodule on follow up should also be considered significant, even if the size has remained stable \((42)\). As size or attenuation increase so too does the risk of malignancy \((16)\).

The Fleischner Society has introduced recommendations for the management of subsolid pulmonary nodules detected at CT \((35)\). Despite a lack of strong evidence the guidelines are based on expert consensus and extensive literature searching and are the current gold-standard in the management of subsolid nodules. The guidance is essential reading for any radiologist involved in the follow up of these nodules and are summarized below and in Table 2.

Solitary GGNs that measure less than 5 mm do not require any further follow-up. It is unknown exactly how frequently these would progress to invasive adenocarcinomas, their small size precludes any meaningful interval assessment given a doubling time likely to be many years, and such follow up would have financial implications and expose patients to increased radiation.

Pure GGNs greater than 5 mm require an interval scan to determine persistence and subsequently annual surveillance for at least 3 years with contiguous thin slice CT if they remain unchanged. Figure 7 demonstrates a GGN that increased in size and attenuation over a period of 7 years. Although these lesions can be benign in up to 20% \((43)\), without a truly accurate method to assess malignant potential other than surgical resection and because of the greater likelihood of these representing AAH/AIS/MIA they require surveillance to detect signs of evolving malignancy as described including increased size, attenuation or solid component.

In contrast to pure GGNs, subsolid nodules, particularly those with a solid component greater than 5 mm are considered malignant until lack of growth is demonstrated at interval CT in 3 months. The greater the size of the
Table 2: Summary of the Fleischner Society guidelines for the management of subsolid pulmonary nodules (10)

<table>
<thead>
<tr>
<th>Nodule type</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solitary pure GGN &lt;5 mm (assessed with contiguous CT sections of &lt;1 mm)</td>
<td></td>
</tr>
<tr>
<td>≤5 mm</td>
<td>No follow up</td>
</tr>
<tr>
<td>&gt;5 mm</td>
<td>Follow up with CT at 3 months, and then yearly monitoring for a minimum of 3 years if persistent and unchanged. (FDG-PET is of limited value and therefore not recommended)</td>
</tr>
<tr>
<td>Subsolid GGNs</td>
<td></td>
</tr>
<tr>
<td>&lt;5 mm</td>
<td>Follow up with CT at 3 months to confirm persistence. If persistent and solid measuring &lt;5 mm, then yearly CT monitoring for a minimum of 3 years</td>
</tr>
<tr>
<td>≥5 mm</td>
<td>If persistent and solid measuring ≥5 mm, then biopsy or surgical resection should be considered. If subsolid nodules measure &gt;10 mm FDG PET should be considered for further evaluation</td>
</tr>
<tr>
<td>Multiple subsolid nodules</td>
<td></td>
</tr>
<tr>
<td>Pure GGNs ≤5 mm</td>
<td>Follow up with CT at 3 months to confirm persistence</td>
</tr>
<tr>
<td>Pure GGNs &gt;5 mm with no dominant lesion</td>
<td>Follow up CT at 2 and 4 years to monitor. If persistent and solid measuring &lt;5 mm, then yearly CT monitoring for a minimum of 3 years</td>
</tr>
<tr>
<td>Dominant nodule with subsolid or solid component</td>
<td></td>
</tr>
<tr>
<td>GGN, ground glass nodule; CT, computed tomography.</td>
<td></td>
</tr>
</tbody>
</table>

Figure 7: (A) A pure GGN in a patient with previously resected invasive adenocarcinoma; (B) the patient was lost to follow up and presented 5 years later at which point the nodule was of slightly higher attenuation; (C) 1 year later there is a clear solid component highly suggestive of progression to invasive adenocarcinoma. GGN, ground glass nodule.
solid component the more likely it is amenable to accurate CT biopsy and assessment with PET particularly once measuring 8-10 mm. CT guided biopsy of GGNs using co-axial biopsy technique, has been shown to have a diagnostic accuracy of 93% (17).

Multifocal persistent ground glass nodules often represent either primary lung cancers or lung metastases. AAH and pre-invasive adenocarcinomas are more frequently seen in multiple ground glass nodules (44). The Fleischner Society also gives recommendations for the management of multiple GGNs and subsolid nodules. For multiple GGNs of less than 5 mm a conservative approach with surveillance CT at 2 and 4 years is advocated. For multiple nodules greater than 5 mm without a dominant nodule initial CT at 3 months followed by annual CT is advocated. The guidelines introduce the concept of a dominant nodule which if present mandates a more aggressive approach particularly in the presence of a solid component >5 mm.

Summary

The revised classification of lung adenocarcinoma has introduced new terminology to better reflect the multistep progression of lung adenocarcinoma. There is now differentiation between pre-invasive and invasive lesions. This more robust classification replaces the term BAC more accurately reflecting the correlation between radiology, pathology and prognosis. Radiologists play an important role in distinguishing pre-invasive from invasive lesions and must be familiar with the new Fleischner Society recommendations regarding the management of subsolid pulmonary nodules. The classification heralds an exciting era in lung adenocarcinoma. It is likely that suggested changes for nodule measurement and determination of T stage will be reflected in future TNM and WHO classifications.

Acknowledgements

Disclosure: The authors declare no conflict of interest.

References

16. Henschke CI, Yankelevitz DF, Mirtcheva R, et al. CT screening for lung cancer: frequency and significance of


2009;19:552-60.


Cite this article as: Gardiner N, Jogai S, Wallis A. The revised lung adenocarcinoma classification—an imaging guide. J Thorac Dis 2014;6(S5):S537-S546. doi: 10.3978/j.issn.2072-1439.2014.04.05